跳至主要内容
临床试验/NCT06567938
NCT06567938招募中不适用

Intravascular Ultrasound-Guided or Angiography-Guided Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease: The IVUS-CKD Trial

First Affiliated Hospital Xi'an Jiaotong University1 个研究点 分布在 1 个国家目标入组 1,528 人开始时间: 2024年7月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,528
试验地点
1
主要终点
Target vessel failure (TVF), including cardiac death, target vessel myocardial infarction (MI), or clinically driven target vessel revascularization (TVR)

研究概览

简要总结

The IVUS-CKD study is a prospective, randomized controlled, multicenter trial to determine whether the intravascular ultrasound (IVUS)-guided percutaneous coronary intervention is superior to the angiography-guidance in chronic kidney disease (CKD) patients with respect to target vessel failure (TVF) at 12 months after randomization.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CKD patients with eGFR<60 mL/min/1.73 m^2
  • De novo coronary lesion suitable for second-generation metallic drug-eluting stent placement and IVUS imaging
  • Signed written informed consent

排除标准

  • Onset of STEMI within 24 hours or emergent angiography
  • Pregnant or childbearing women
  • Co-morbidity with an estimated life expectancy of < 1 year
  • LVEF ≤ 30%
  • Cardiogenic shock or hemodynamic instability
  • Severe hepatic dysfunction, defined as ALT or AST more than 5 times the ULN
  • PCI within the previous 12 months
  • Target lesion of stent thrombosis or in-stent restenosis
  • Any planned non-cardiac surgery within 12 months
  • Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk
  • Current enrolment in other clinical trials
  • Contraindication to anti-platelet agents
  • History of intracranial or gastrointestinal bleeding requiring transfusion or surgical intervention for control (excluding hemorrhoid)
  • Chronic total occlusion lesion with unsuccessful guidewire crossing
  • Current intake of nephrotoxic medications (e.g., nonsteroidal anti-inflammatory drugs except acetylsalicylic acid, phenylbutazone, aminoglycosides, amphotericin B, polymyxin, platinum complexes)
  • Immune-related kidney disease or on hormone therapy (e.g. lupus nephritis, IgA nephropathy)
  • Planned exposure to contrast within 72 h after the procedure, intravascular administration of contrast within the previous 5 days
  • Intake of anticoagulants
  • Hemoglobin <60 g/L
  • Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial
  • Patients allergic to metals or contrast

结局指标

主要结局

Target vessel failure (TVF), including cardiac death, target vessel myocardial infarction (MI), or clinically driven target vessel revascularization (TVR)

时间窗: 12 months

The difference in TVF will be calculated from 0 month to 12 months between IVUS- and Angiography-guidance groups.

次要结局

  • Hierarchical composite of target vessel failure(12 months)
  • 30-day cardiorenal endpoint(30 days)
  • Cardiac death(12 months)
  • Target vessel MI(12 months)
  • Clinically driven target vessel revascularization(12 months)
  • Spontaneous MI(12 months)
  • Target vessel failure excluding periprocedural MI(12 months)
  • Clinically driven target lesion revascularization(12 months)
  • Target lesion failure(12 months)
  • Major adverse cardiovascular event(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验